ObsEva

97 articles about ObsEva

• ObsEva To Hold First Quarter 2017 Financial Results And Business Update Call On Thursday, May 18, 2017

  5/11/2017

• ObsEva Initiates Phase III Clinical Program For OBE2109 In Uterine Fibroids

  4/25/2017

• ObsEva To Present Pharmacology Results Demonstrating OBE022 Exerts A Synergistic Effect In Combination With Standard Of Care In Animal Model For Preterm Labor

  3/17/2017

• ObsEva Starts Phase III Clinical Program For Nolasiban In ART

  3/7/2017

• Women's Health Biotech ObsEva to Open Up U.S. HQ in Boston After $97 Million IPO

  1/30/2017

• ObsEva Release: Pharma To Ring The Nasdaq Stock Market Opening Bell In Celebration Of Its IPO

  1/26/2017

• ObsEva Release: Pharma Announces Pricing Of Initial Public Offering

  1/26/2017

• ObsEva Release: Company Expands Leadership Team And Board Of Directors With Industry Veterans

  1/17/2017

• ObsEva Release: Company Announces Completion Of Phase I First-In-Women Study Of OBE022 For The Treatment Of Preterm Labor

  1/13/2017

• ObsEva Announces Plans To Conduct Initial Public Offering In The United States

  10/17/2016

• ObsEva To Webcast Presentation At 15th Annual Needham Healthcare Conference

  4/5/2016

• ObsEva Strengthens Board With Appointment Of Biotechnology Veteran Dr. Frank Verwiel

  3/24/2016

• ObsEva And Kissei Pharmaceutical Co., Ltd. Announce Global Agreement To Develop And Commercialize KLH-2109 For The Treatment Of Endometriosis

  11/20/2015

• ObsEva Announces Recruitment Of The First Patient In TERM Phase 2 Study

  6/23/2015

• ObsEva Reports Positive Phase 1 Results For The First Orally Active Oxytocin Antagonist OBE001 To Treat Preterm Labour

  2/26/2015

• ObsEva Announces The Initiation Of A Pivotal Phase 2 Study To Evaluate OBE001 For Improving Embryo Implantation And Clinical Pregnancy Rate In Women Undergoing IVF/ICSI

  11/18/2014

• ObsEva Lands $34.5 Million Series A Funding, License Agreement With Merck Serono

  8/29/2013